Investor Presentation

Mgmt Guided Margin ImprovementInvestor Communications View source PDF

SMSPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.5%1-day move

₹381.50

prior close

₹385.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.1-1.3-2.1-3.2-1.5-0.7-2.8-6.0-5.5-7.2-1.3-1.1+2.8—

Up moveDown movePending

AI summary

SMS Pharmaceuticals reported strong FY26 results with PAT up 48% YoY to ₹102 crore, driven by backward integration and improved product mix. Revenue grew 13% to ₹887 crore while EBITDA margin expanded 155 bps to 19%. The company achieved gross margin of 44% in FY26, up from 36% in FY17, through high-value product mix and backward integration projects. Q4FY26 showed revenue of ₹238 crore (down 4% YoY) but PAT up 61% to ₹33 crore. The ₹280 crore capex programme remains on track for FY27 completion, targeting capacity expansion for existing APIs and new pipeline products. The board recommended a final dividend of ₹0.40 per share.

Likely market impact

Strong margin expansion driven by backward integration and high-value product mix signals operational efficiency gains. The doubling of R&D investment and 20 new DMF filings over 24 months could support future revenue growth, though the sequential Q4 revenue decline warrants monitoring.